<DOC>
	<DOC>NCT01305551</DOC>
	<brief_summary>The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Metformin from a 5 mg Saxagliptin/500 mg Metformin extended release (XR) fixed dose combination (FDC) tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR (marketed in Brazil by Merck S.A.) tablets administered together in both the fasted and fed states.</brief_summary>
	<brief_title>BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States</brief_title>
	<detailed_description>Primary purpose: To demonstrate the bioequivalence of Saxagliptin and Metformin from a 5 mg Saxagliptin/500 mg Metformin XR FDC tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR (marketed in Brazil by Merck S.A.) tablets administered together in both the fasted and fed states.</detailed_description>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Healthy men and women Women of childbearing potential (WOCBP) who are using acceptable method of contraception Women who are not nursing History of Gastrointestinal (GI) disease Any GI surgery that could impact study drug absorption History of allergy to drug class or related compounds History of allergy to metformin or other similar acting agents. History of any significant drug allergy. Estimated creatinine clearance (ClCr) &lt; 80 mL/min using CockcroftGault formula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>